Home > Harmony in Hematology
It’s all about Big Data in Hematology. Your Big Data! Big Data will have an impact on health and in particular on the development of new drugs and therapies for patients. Blood cancers, or hematologic cancers (e.g. leukemia, lymphoma, and myeloma), affect the production and function of blood cells and account for about 40% of cancer cases in children and about one third of cancer deaths. As many blood cancers are rare, and healthcare practice varies across EU, a lack of data on relevant outcomes represents a challenge for clinicians, researchers, and other decision-makers like regulators and HTA bodies, resulting in limitations for patient access to the best healthcare. The HARMONY Alliance aims to use "Big Data and Big Data analytics" to deliver information that will help to improve the care of patients with these diseases.
HARMONY is the acronym for: Healthcare Alliance for Resourceful Medicine Offensive against Neoplasms in Hematology.
All Partners and Associated Members share the same goal: to address the present challenges effectively, to provide data, and to participate in communication activities. This network will build upon the work carried out by existing European and national cooperative groups.
HARMONY was initiated in January 2017 for a period of five years, and is funded through the European Union's (EU's) Innovative Medicines Initiative (IMI). Capitalizing on its strong drive to succeed, on a spirit of international cooperation, and on the availability of high-speed technologies, HARMONY will facilitate better access to therapy, improved patient care, and a higher quality of life, all accomplished in compliance with legal, ethical, and governance rules. Its results will evolutionize the treatment of hematologic malignancies (HMs).
Hematologic malignancies with a high unmet need in adult and pediatric patients are: